Trypanosoma cruzi trans-sialidase (TS) constitutes a key molecule in both the establishment of the infection and in the development of pathologic abnormalities associated with Chagas disease. Several cross-reactive epitopes located in its catalytic region were previously identified. In the present study, a panel of enzymes altered in these epitopes were generated to analyze their in vivo significance. Although displaying similar specific activity, thermal stability, and overall antigenic structure, mutant TS proteins elicited an improved neutralizing response, compared with that in the parent, wild-type molecule. These features support an in vivo role for cross-reactive epitopes in dampening the elicitation of TS-neutralizing antibodies. Structural and immunological evidence indicating that the epitope cross-reactivity could be extended to the highly immunogenic SAPA repeats located on the TS C terminus is also reported. This complex cross-reactive epitope cargo might represent a novel strategy, providing secreted virulence factors with the ability to delay an effective elicitation of humoral response.
surface molecules [8] [9] . trans-Sialylation of T. cruzi surface components such as the Ssp3 epitope and mucin-like molecules promotes cell invasion and precludes the action of lytic antibodies [10] [11] [12] . On the other hand, TS plays a key role in the immunomodulation of the infected host. As has recently been described elsewhere, administration of the soluble enzyme to mice induces polyclonal B-cell hyperreactivities [13] and marked thymic involution [14, 15] , 2 events that characterize the acute phase of Chagas disease.
Antibodies able to neutralize TS activity (TS-NtAbs) are normally found in patients with chronic Chagas disease and in animals infected with T. cruzi [16] [17] [18] ; however, the onset of this antibody response is delayed until the end of the acute phase and coincides with a decline in parasitemia levels [16] . Passivetransfer experiments in laboratory animals have further addressed the protective role of TS-NtAbs [15] . It is therefore conceivable that the parasite might have developed mechanisms to prevent antibody-mediated TS neutralization during the initial steps of infection. In this context, it is worth noting the presence of a highly immunogenic repetitive domain (termed "SAPA") on the TS C-terminus [19, 20] . In contrast to TS-NtAbs, anti-SAPA antibodies are nonprotective and can be detected as early as 7 days postinfection [16] . Alternative immunomodulatory mechanisms, such as the simultaneous expression of multiple related molecules belonging to the TS superfamily, have been proposed [3] [4] [5] .
On the basis of crystallographical and immunological data, we have recently shown that the catalytic region of TS contains several antigenic determinants located in solvent-exposed areas [21, 22] . A salient feature of these epitopes is that they are antigenically related and nonneutralizing, suggesting that they might play a direct role in evasion of immunity to TS [22] . In Figure 1 . Cloning strategy of mutant trans-sialidase (TS) molecules. Shown are an in-scale representation of the TS-13R open reading frame and, below it, the 3-domain structure of the encoded protein as defined by Buschiazzo et al. [21] . Oligonucleotides (arrows) and restrictionendonuclease sites used for deletion of epitopes 1441 and 1443 are indicated. "ATG" denotes the translation start codon. the present work, we have constructed a panel of mutant TS molecules to address this issue.
Materials and Methods
Animals. Female C3H/HeN 60-90-day-old mice bred in our facilities were used.
Immunization protocols. The mice were intravenously (iv) injected with enzymes contained in 150-200 mL of sterile PBS. The immunizing schedule consisted of 3 doses (15, 5, and 5 mg), administered at 15-day intervals.
Synthetic peptides. Peptides were custom synthesized by Sigma-Genosys, by the following sequences: 1441 (WQPIYGSTP-VTPTGSC), 1443 (TPADPAASSSERGC), and 1441-rangeli (WQ-PIYGAAPASPTGSC). Peptides 1439, 1440, and 1-5 have been described elsewhere [22] . Two additional T. cruzi mucin-derived peptides-Loc5 (TASGDQKQAEQETC) and E3 (TASGQKAE-KETC)-were kindly provided by Dr. A. C. C. Frasch, a member of our institute. Peptides were coupled, via their cysteine residue, to Imject maleimide-activated keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA) (both from Pierce), according to the manufacturer's guidelines.
Antiserum. Antiserum to KLH-coupled peptides was raised in rabbits, as described elsewhere [22] . Antiserum against the nonrepetitive region of TS was raised in mice immunized with a TS molecule lacking SAPA repeats [23] . Anti-SAPA serum raised against recombinant proteins genetically fused to SAPA and to an uncoupled synthetic peptide spanning the sequence of 2 SAPA units has been described elsewhere [20] .
Dot-spot assay. BSA-coupled peptides and recombinant proteins (300 ng each) were spotted onto nitrocellulose membranes in a defined array. Filters were blocked with 0.025 M Tris-HCl (pH 7.6), 0.15 M NaCl, and 0.1% Tween-20 (TBS-T) plus 5% nonfat milk and were probed with the indicated antiserum at 1:300 dilution. After extensive washings with TBS-T, filters were processed with horseradish peroxidase-conjugated secondary antibodies (DAKO), followed by chemiluminescence detection.
Cloning of chimeric TS molecules. Mutant enzymes were constructed by polymerase chain reaction (PCR), on the basis of the TS-13R clone [24] , as schematized in figure 1 . For the cloning of the TS lacking epitope 1441, primer 3 (CGGTGACGATTCACG-AGGTT) was used in combination with either primer 6 (GTGGT-ACCTCTTACCCATCTCCCAGGATCCGGTCGGCGACGC-CGGCGCTGCTCCGTATAT) or primer 7 (GTGGTACCTC-TTACCCATCTCCCAGGATCCGGTCGGCGACGCCCCCG-CTGCTCCGTATAT). Primer 6 codes for the sequence homologous to that of epitope 1441 (WQPIYGAAPASPTGS), which is present in T. rangeli sialidase [25] , whereas primer 7 introduces a single glycine-for-proline substitution (WQPIYGAAGASPTGS). Both products were NruI/KpnI digested and were substituted for the corresponding NruI-KpnI fragment in the TS-13R clone, to generate clones D1441 and D1441(DPro), respectively. The clone lacking epitope 1443 was constructed according to a 2-step PCRbased strategy. In the first step, 2 reactions were performed that used both the TS-13R clone as template and the following oligonucleotides: 2 (GTtctagaGGTCCTGCTGTCACCACGGT) in combination with 5 (CTCGCACCCAGCAAAGGACT) and 1 (GCG-AGCTACGGATCATTAAA) in combination with 4 (GCtctagaAATGCTGGACAGGTGGCTG). Oligonucleotides 2 and 4 harbor an XbaI restriction site (denoted, in the preceding sequences, by lowercase letters), thus rendering 2 products that, in their 3 and 5 termini, respectively, contain a unique XbaI cloning site. Proper ligation of both products by this XbaI site resulted in a TS fragment that lacks epitope 1443. Ligation products were separated by elecDownloaded from https://academic.oup.com/jid/article-abstract/186/3/397/847319 by guest on 26 January 2019 were neutralized by serum from a patient with Chagas disease, at similar seric dilution (i.e., 1:80, except in the case of TS-13R, for which the dilution was 1:160). NS, below the sensitivity of the assay; ND, not determined. c "TS(1)," "TS(2)," and "TS(3)" refer to 3 samples of antiserum raised, in mice, against parental TS lacking the SAPA repeats.
trophoresis in 2% agarose gel, and the desired band was excised and used as template for a second PCR, which used oligonucleotides 5 and 1. The product was PstI/NruI digested and was substituted for the corresponding PstI-NruI fragment in the TS-13R clone, to generate the D1443 clone. The double-mutant (DM) clone, which has both epitope deletions, was constructed by substituting the PstI-NruI fragment present in the D1443 clone for that present in the D1441 clone. The unique XbaI site present in the DM clone was used to supplement the latter with epitope 1441, by means of primers 1441s (CTAGCTGTCCAATATACGGATCAACGCCG-GTGACGCCGACCTGTA) and 1441as (CTAGTACAGGTCG-GCGTCACCGGCGTTGATCCGTATATTGGACAG), to generate the DMϩ1441 clone. Mutant enzymes were confirmed by DNA sequence analysis of relevant regions, by the Sequenase 2.0 kit (U.S. Biochemical).
Expression and purification of TS molecules. TS molecules were expressed in Escherichia coli, as a C-terminal fusion of the stretch of histidines provided by the pTrcHis cloning vector (Invitrogen). Purification to a single band in Coomasie blue-stained SDS-PAGE was achieved as described elsewhere [23] .
TS assay. Enzymatic activity of purified TS molecules was assayed by measurement of the amount of sialic acid residue transferred from sialyllactose (Sigma Chemical) to [ 14 C]-lactose (Amersham-Pharmacia Biotech) [23] . One unit of TS was defined as the amount of enzyme able, under standard conditions, to transfer 10 nM of sialyl residue to lactose in 1 min.
TS-inhibition assay (TIA). Inhibitory antibodies were tested by measurement of the remnant TS activity after incubation of 2 mL of TS (2 ng), able to render ∼2500 cpm in 30 min, with 12 mL of serum. Each sample was assayed in duplicate, and the means were expressed as TIA values. Serum samples obtained either from healthy individuals or from naive mice were used as controls for each assay and were recorded as 0% TIA. TIA values !25% were considered to be negative, owing to methodological concerns [23] .
ELISA. Polystyrene ELISA microplates (Maxisorp; NUNC) were coated with affinity-purified rabbit anti-SAPA IgG (1 mg/well). After the plates had been blocked with TBS-T supplemented with 5% nonfat milk, a solution containing 2 mg of the indicated protein/ mL was added, the mixture was incubated for 1 h, and the plates were washed with TBS-T. Serum samples were tested at serial dilutions for 2 h and were revealed by the addition of horseradish peroxidase-conjugated secondary antibodies (DAKO) followed by 2,2 -azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Roche Diagnostics). Each sample was tested in triplicate. Serum samples obtained from naive mice and assayed in the same plate were used as controls. [22] . To assess their actual in vivo role, a collection of TS molecules altered by site-directed mutagenesis were generated. Epitope 1443 protrudes from the protein core, as a highly flexible loop that is fixed, at the base, by a disulfide bridge [21] . This particular feature suggested to us that the complete loop sequence, including its flanking cysteine residues, might be altered or even removed, without introducing major structural and/or functional changes in the overall TS molecule. On the other hand, the enzyme bearing modified epitope 1441 was generated by replacing part of its sequence ( 566 YGSTPVTPTGS 576 ) either by the homologous sequence present in T. rangeli sialidase (YGAAPASPTGS) or by the highly related sequence YGAAGASPTGS. The effect that these replacements has on recognition of the antibody was analyzed by dot-spot assay using synthetic peptides spanning the sequence of the original epitope, 1441, and that derived from T. rangeli sialidase (termed "peptide 1441-rangeli"). As shown in figure 2 , peptide 1441-rangeli was not recognized by antiserum raised against peptides 1439, 1440, 1443, 3, and 4, in contrast to what was seen for peptide 1441 (also see [22] ). Complementary evidence was provided by anti-peptide 1441-rangeli serum, which did not display cross-reactivity for TS-derived peptides other than 1441 (figure 2). Together, these 2 types of evidence indicate that the minor substitutions described above were enough to functionally disrupt epitope 1441. TS molecules carrying these 2 kinds of modifications were therefore named "D1441" and "D1441(DPro)," respectively (table 1) . Additional molecules, including the DM clone, which has both epitope deletions, and the DMϩ1441 clone, which has epitope supplementation, also were generated (table 1) .
Results

Construction of mutant
Molecular characterization of mutant enzymes. The specific activities recorded for mutant TS molecules were close to both that recorded for the TS-13R parental molecule (table 1) and that recorded for the natural enzyme purified from trypomastigote supernatants [23] . In addition, they displayed similar kinetics of inactivation at 37ЊC in PBS plus 100 mg of BSA/mL, when evaluated as described by Buscaglia et al. [23] . For this assay, remnant TS activity was recorded for aliquots sampled after 0.5, 5, 25, and 50 h of incubation. All of the enzymes showed 77%-85% of input activity after 50 h of incubation.
TS-NtAbs are directed toward discontinuous epitope(s) [23] . Therefore, inhibition by TS-NtAbs present in serum samples from patients with Chagas disease can be considered to be indicative of proper folding and preservation of the neutralizing epitope(s) in mutant TS molecules. All the TS molecules, whether parental or mutant, were titered out by TIA using similar dilutions (either 1:80 or 1:160) of serum from a patient with Chagas disease. None of the enzymes was neutralized by the addition of either normal or anti-SAPA serum (data not shown) [16] . For further insights into their overall antigenic structure, equal amounts of mutant enzymes were anchored to ELISA plates, via the common SAPA extension (figure 1). The reactivity of a panel of samples of anti-TS serum was then assayed, rendering similar titers with the different molecules (table 2). This panel included antiserum samples raised against each of 4 synthetic peptides-1439, 1, 3, and 5-spanning the sequence of nonoverlapping epitopes identified in the catalytic region of TS [22] . In addition, 3 antiserum samples directed toward the entire TS catalytic region [23] produced closely similar ELISA titers (table 2) . Taken together, these results strongly suggest that the modifications introduced into mutant TS molecules did not affect either their proper folding, their functionality, or their overall antigenic structure.
In vivo evaluation of mutant TS molecules. To evaluate the effect that these epitopes have on the kinetics of TS-NtAbs induction, we administered mutant TS molecules to mice via iv injection, mimicking the actual course of TS dissemination during infection [16, 26] . Given that the immunogenicity of ivinjected TS depends on its serum persistence [23] , the half-life of mutant molecules was measured in blood; the results were similar to those for the parental TS-13R molecule (data not shown) [24] . Mice received 2 doses of the recombinant molecules, and, 7 days after each dose, serum samples were collected and assayed by TIA. Inhibition results depicted in figure 3 were obtained by use of a parental TS molecule as enzyme source, further corroborating that the neutralizing epitope(s) remains unaltered in the mutant molecules.
Enzymes D1441, D1441(DPro), and D1443 produced a neutralizing response earlier than that of the parental TS-13R molecule ( figure 3 ). In the case of D1441, TS-NtAbs were detected in 5 of 6 mice immediately after the first dose. Overall, molecules devoid of epitope 1441 seemed to elicit a better neutralizing response than did molecules lacking epitope 1443. As depicted in figure 3 , 86% (12/14) of mice injected with either the D1441 or the D1441(DPro) molecules produced positive TIA values, whereas this percentage was lowered to 64% (7/11) in the group of mice injected with the D1443 molecule. In contrast, TS-NtAb response was elicited in only 14% (2/16) of mice injected with the TS-13R molecule after the second dose.
In a second set of experiments, DM, the enzyme lacking both epitopes, was tested. Of 6 mice tested, 4 (67%) showed positive TIA values, and results for 1 additional mouse were considered to be borderline (figure 3). These results were similar to those obtained with the simple mutants, suggesting that the effect of these epitopes was not cumulative. The role of epitope 1441 was further evaluated by inserting this sequence into the DM clone. To ensure the delineation of a solvent-exposed loop, the sequence was constrained, by a disulfide bridge, within the region between the 2 cysteine residues, for consistency with the situation of the original epitope 1443. Interestingly, mice injected with this molecule (termed "DMϩ1441") showed a marked reduction in elicitation of TS-NtAbs (figure 3). Only 2 (40%) of 5 mice injected with this molecule were considered to be TIA positive at the end of the immunization schedule, and their values were not 150% of neutralization in any case. These results indicate the central role that epitope 1441 plays in the delay of elicitation of TS-NtAbs.
The mice were administered an additional dose of the corresponding molecule and then were bled 1 month later to determine their final TS-NtAbs titer. TIA-positive reactions were recorded for every mouse immunized with D1441, D1441(DPro), D1443, and DM proteins, up to 1:5 dilution. In some cases, neutralizing activity was observed even at 1:10-1:50 dilution. In contrast, serum samples collected from TIA-positive mice immunized with either the DMϩ1441 or the TS-13R molecule rendered negative results at 1:5 dilution. These results suggest that the amount of TS-NtAbs elicited by the former molecules was increased by 5-10 fold.
Antigenic homology among SAPA and epitopes 1441 and 1443. SAPA repeats constitute the immunodominant portion of the TS molecule, as evidenced by infection and immunization data [27] . We found significant amino acid sequence homologies between the repetitive unit of SAPA and those of epitopes 1441 and 1443 (figure 4). Thus, one interesting hypothesis is that the anti-SAPA antibody response might be related to the network of cross-reactive B-cell responses elicited toward the catalytic region of the molecule. To evaluate this possibility, we analyzed the reactivity that a panel of anti-SAPA serum samples had toward BSA-coupled peptides spanning the sequence of different epitopes, by dot-spot assay. Mouse antiserum raised against GST-SAPA showed reactivity toward peptide 1443, whereas this recognition was extended to peptide 1441 when serum raised in rabbit was used as the probe ( figure 4) . Interestingly, the recognition that rabbit antiserum displayed toward peptide 1441-rangeli was severely hampered (figure 4). In addition, peptide 1441 was recognized by anti-b-galactosidase-SAPA serum and, to a lesser extent, by an anti-SAPA peptide serum. T. cruzi mucinderived peptides coupled to BSA and assayed under the same conditions rendered consistently negative results, thus corroborating the specificity of the signals (figure 4). Complementary evidence for this cross-reaction was restricted to anti-peptide 1441 serum (figure 2).
Discussion
A common strategy displayed by several pathogens is the presentation of immunodominant epitopes to vitiate the ability of the immune system to focus on protective targets [28] [29] [30] . In protozoa, this scenario has been addressed for tandemly repeated motifs promiscuously inserted into a wide range of proteins [3, 27, [31] [32] [33] [34] . Alternative devices, such as molecular mimicry either with host molecules or among simultaneously expressed antigens, have also been ascribed to protozoan pathogenesis [7] and immune evasion [35] . On the basis of this knowledge and T. cruzi infection data, we hypothesized that, along with SAPA repeats, the cross-reactive epitope network present in TS might function in vivo to interfere with the elicitation of TS-NtAbs [22] . To test this hypothesis, we generated a panel of recombinant enzymes deleted and/or functionally altered in some of these epitopes (table 1 and figure 2 ). The use of TS mutants was validated, since they showed similar heat stability and specific activity and displayed a recognition profile similar to that of the parental molecule, when tested against an extensive panel of anti-TS serum samples (tables 1 and 2). In addition, neutralizing epitope(s) was conserved among TS mutants, since it (a) was inhibited by serum from patients with Chagas disease (table 2) and (b) elicited antibodies able to neutralize the parental TS molecule (figure 3). It is worth noting that the entire loop, including the flanking cysteines containing epitope 1443, is absent from the numerically prominent 82-90-kDa enzymatically inactive members of the TS-like antigen family (see figure 5 ) [3, 8] . The mutant TS devoid of this loop (i.e., D1443), however, displayed specific activity similar to that of the parental molecule (table 1) but produced an improved TS-NtAb response when injected into mice ( figure  3 ). These features enable us to suggest that the main purpose of the insertion of this sequence into the TS-protein framework is to subvert the elicitation of the TS-neutralizing response.
The immune role of epitopes 1441 and 1443 was evaluated by monitoring the TIA response after injection of mutant enzymes into mice. As shown in figure 3 , dampening of either epitope 1441 or epitope 1443 led to a refocusing of the anti-TS antibody response, toward neutralizing epitope(s). Although moderate, the amount of TS-NtAbs elicited by mutant enzymes was in the range of infection titers [16, 17] . More important, mice injected with these altered molecules showed an earlier onset of elicitation of TS-NtAbs, and the magnitude of this response was 5-10-fold enhanced, compared with that in control mice (figure 3). Compatible with the epitope network-diversion hypothesis, simultaneous dampening of both epitope 1441 and epitope 1443 did not produce a cumulative effect (figure 3). Among selected epitopes, 1441 seemed to play a major role in the cross-reactive network, as indicated by 3 independent types of evidence. First, molecules devoid of this epitope elicited a better neutralizing response than did molecules lacking epitope 1443 ( figure 3 ). The contribution of the Pro 570 residue to this phenomenon is not significant, as is indicated by results obtained with the D1441(DPro) molecule. Second, the DMϩ1441 construct, displaying the sequence of epitope 1441 on a highly exposed cysteine-constrained loop, diminished TS-NtAbs nearly to control values, even in the absence of epitope 1443 (figure 3). Finally, recognition of peptide 1441 was verified for every antiserum raised against TS-derived peptides (figure 2).
Another interesting finding was that SAPA, a highly immunogenic component of the enzyme [27] , is antigenically related to epitopes 1441 and 1443 (figure 4). The basis for this cross-reactivity might be the amino acid sequence homologies depicted in figure 4 . Epitope 1443 spans the sequence DPAASS, which serves as one of the major SAPA epitopes (sequence TPADSS) detected by mouse infection serum, whereas epitope 1441 harbors the sequence STPVTP, which highly resembles the major SAPA epitope (sequence STPSTP) recognized by human Chagasic serum) [20] . The unique mismatch observed (i.e., Val for Ser) involves a noncritical position for this epitope [20] . The cross-recognition of such SAPA-like sequences by anti-SAPA antibodies might trigger the humoral response toward the catalytic region. Further studies of the molecular mechanisms leading to this epitope spreading will help to clarify this issue. Because none of the antiserum to catalytic region-derived peptides (except for epitope 1441) recognized SAPA repeats (figure 2), it might be hypothesized that, after the elicitation of anti-SAPA antibodies, the wave of antibody cross-reaction progresses mainly toward different cross-reactive determinants located in the catalytic region. In this regard, it is worth noting that epitope 1441-rangeli, which led to an improved neutralizing response (figure 3), was poorly recognized by antiserum raised against TS-derived peptides (figure 2) and SAPA repeats (figure 4).
As revealed in this study, T. cruzi TS displays a functional network of B-cell cross-reactive epitopes that interplay with the immunodominant SAPA repeats, to delay the immune neutralization of TS. As far as we know, this is the first report showing the coexistence of both kinds of evasive mechanisms within a single parasite molecule. Their orchestrated action drives the immune system into a series of nonneutralizing, spurious antibody responses, thus providing the enzyme with an extended period of time to exert its immunomodulatory effects [14, 15] . This phenomenon might constitute a novel adaptive strategy to shield a virulence factor that is shed into a hostile milieu.
